Breast Disease: Benign and Malignant

Medical Clinics of North America

Volumn 92, Issue 5, 2008, Pages 1115-1141

  Meisner, Angela L W ^a   Houman Fekrazad, M ^a   Royce, Melanie E ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BROMOCRIPTINE; BUTYROPHENONE DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORPROMAZINE; CIPROFLOXACIN; CLINDAMYCIN; DANAZOL; DIGOXIN; ERYTHROMYCIN; MAGNESIUM; METHYLDOPA; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; OXYMETHOLONE; PARACETAMOL; PENICILLIN DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PREDNISONE; PRIMROSE OIL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE; TAMOXIFEN; THIOXANTHENE DERIVATIVE; TOREMIFENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VANCOMYCIN;

BREAST; BREAST CANCER; BREAST DISCHARGE; BREAST DISEASE; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ECHOMAMMOGRAPHY; EPITHELIUM HYPERPLASIA; FAT NECROSIS; FIBROADENOMA; GALACTORRHEA; GENE MUTATION; GENETIC DISORDER; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; MAMMOGRAPHY; MASTALGIA; MASTITIS; MORBIDITY; NIPPLE MALFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC THERAPY; TREATMENT OUTCOME;

BREAST DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 49449104443     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2008.04.003     Document Type: Review

References (55)

1. Goehring C., and Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 19 2 (1997) 310-327
2. Courtillot C., Plu-Bureau G., Binart N., et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 10 4 (2005) 325-335
3. Bartow S.A., Pathak D.R., Black W.C., et al. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 60 11 (1987) 2751-2760
4. Barton M.B., Elmore J.G., and Fletcher S.W. Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation, and outcome. Ann Intern Med 130 8 (1999) 651-657
5. Millet A.V., and Dirbas F.M. Clinical management of breast pain: a review. Obstet Gynecol Surv 57 7 (2002) 451-461
6. Rosolowich V., Saettler E., Szuck B., et al. Mastalgia. J Obstet Gynaecol Can 28 1 (2006) 49-71
7. Lester S.C., and Cotran R.S. The breast. In: Cotran R.S., Kumar V., and Collins T. (Eds). Lester and Cotran, 1999 pathologic basis of disease. 6th edition (1999), W.B. Saunders Company, Philidelphia 1093-1119
8. Silva O.E., and Zurrida S. Benign breast disease. Breast cancer: a practical guide. 3rd edition (2005), Elsevier Saunders, Endinburgh 1-11
9. Dixon J.M., Anderson T.J., Lumsden A.B., et al. Mammary duct ectasia. Br J Surg 70 10 (1983) 601-603
10. Kitahara S., Wakabayashi M., Shiba T., et al. Mammary duct ectasia in children presenting bloody nipple discharge: a case in a pubertal girl. J Pediatr Surg 36 6 (2001) e2
11. Tuli R., O'Hara B.J., Hines J., et al. Idiopathic granulomatous mastitis masquerading as carcinoma of the breast: a case report and review of the literature. Int Semin Surg Oncol 4 (2007) 21
12. Baslaim M.M., Khayat H.A., and Al-Amoudi S.A. ldiopathic granulomatous mastitis: a heterogeneous disease with variable clinical presentation. World J Surg 31 8 (2007) 1677-1681
13. Chow J.S., Smith D.N., Kaelin C.M., et al. Galactography-guided wire localization of an intraductal papilloma. Clin Radiol 56 (2001) 72-83
14. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 7th edition (2004), Lippincott Williams and Wilkins, Philadelphia 1633-1726
15. Kaelin C.M. Paget's disease. In: Harris J.R., Lippman M.E., Morrow M., et al. (Eds). Diseases of the breast. 3rd edition (2004), Lippincott Williams and Wilkins, Philadelphia 1007-1031
16. Dupont W.D., and Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312 (1985) 146-151
17. Ashbeck E.L., Rosenberg R.D., Stauber P.M., et al. Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16 3 (2007) 467-472
18. Schnitt S.J., and Connolly J.L. Pathology of benign breast disorders. In: Harris J.R., Lippman M.E., Morrow M., et al. (Eds). Diseases of the breast. 2nd edition (2000), Lippincott Williams and Wilkins, Philidelphia 75-93
19. Claire S.E., and Morrow M. Management of the palpable breast mass. In: Harris J.R., Lippman M.E., Morrow M., et al. (Eds). Diseases of the breast. 2nd edition (2000), Lippincott Williams and Wilkins, Philidelphia 37-45
20. Kopans D.B. Breast imaging. 3rd edition (2006), Lippincott Williams & Wilkins, Philadelphia p. 749-59
21. Dupont W.D., Page D.L., Parl F.F., et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331 1 (1994) 10-15
22. Orel S.G. High resolution MR imaging for the detection, diagnosis and staging of breast cancer. Radiographics 18 (1998) 903-912
23. Orel S.C. Who should have breast magnetic resonance imaging evaluation?. J Clin Oncol 26 5 (2008) 703-711
24. Mishra S.K., Sharma A.K., Salila M., et al. Efficacy of low fat diet in the treatment of benign breast disease. Natl Med J India 7 2 (1994) 60-62
25. Russell L.C. Caffeine restriction as initial treatment for breast pain. Nurse Pract 14 2 (1989) 36-37 40
26. Fisher B., Costantino J., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 97 22 (2005) 1652-1662
27. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295 (2006) 2727-2741
28. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
29. Dobson R. Breast cancer incidence in US has fallen for first time in 20 years. BMJ 335 7625 (2007) 849
30. Weir H.K., Thun M.J., Hankey B.F., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 17 (2003) 1276-1299
31. Jemal A., Clegg L.X., Ward E., et al. Annual report to the nation on the status of cancer, 1975-2001, with special feature regarding survival. Cancer 101 (2004) 3-27
32. Manson J.E., and Martin K.A. Clinical practice. Postmenopausal hormone-replacement therapy. N Engl J Med 345 1 (2001) 34-40
33. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 24 (2003) 3243-3253
34. Garber J.E., and Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 23 2 (2005) 276-292
35. Greene M.H. Genetics of breast cancer. Mayo Clin Proc 72 1 (1997) 54-65
36. Claus E.B., Risch N.J., and Thompson D. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131 (1990) 961-972
37. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (1989) 1879-1886
38. National Cancer Institute. breast cancer risk assessment tool. Available at: http://www.cancer.gov/bcrisktool. Accessed March 16, 2008.
39. University of Texas Southwestern Medical Center and the BayesMandel Group at Johns Hopkins University. CancerGene with BRCAPRO, MMRpro, and PancPRO. Available at: http://www4.utsouthwestern.edu/breasthealth/cagene. Accessed March 16, 2008.
40. Parmigiani G., Berry D.A., and Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62 (1998) 145-158
41. Parmigiani G, Wang W, Blackford A. BRCAPRO. Available at: http://astor.som.jhmi.edu/BayesMendel/brcapro.html. Accessed March 8, 2008.
42. Fisher B., Costantino J., Redmond C., et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328 (1993) 1581-1586
43. Fisher B., Land S., Mamounas E., et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28 4 (2001) 400-418
44. Fisher E.R., Land S.R., Fisher B., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 100 2 (2004) 238-244
45. Reis-Filho J.S., and Pinder S.E. Non-operative breast pathology: lobular neoplasia. J Clin Pathol 60 12 (2007) 1321-1327
46. Ganz P.A., Day R., Ware Je J.R., et al. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 87 18 (1995) 1372-1382
47. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365 9472 (2005) 1687-1717
48. Baselga J., Perez E.A., Pienkowski T., et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 Suppl1 (2006) 4-12
49. Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 56 (2006) 11-25
50. Orel S.G. MR imaging of the breast. Radiol Clin North Am 38 4 (2000) 899-913
51. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 17 (2002) 3628-3636
52. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
53. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
54. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
55. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 26 (2006) 2733-2743